BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Buy” Rating from HC Wainwright

Posted by Brenda Bartman on Jun 30th, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $32.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 224.38% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wedbush decreased their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday. Needham & Company LLC cut their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Read Our Latest Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Up 3.3%

NASDAQ BCRX traded up $0.32 during midday trading on Tuesday, hitting $9.87. The company had a trading volume of 1,732,538 shares, compared to its average volume of 5,184,810. The firm has a fifty day simple moving average of $8.90 and a two-hundred day simple moving average of $8.27. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $10.94. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -5.54 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same period in the prior year, the company posted $0.20 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals will post -2.66 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after buying an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of BioCryst Pharmaceuticals by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after buying an additional 8,517 shares during the period. Goldman Sachs Group Inc. boosted its stake in BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after buying an additional 640,704 shares in the last quarter. Caxton Associates LLP acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after acquiring an additional 47,355 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.